Andrew J Sauer MD @AndrewJSauer · 02 Sep 2026
The argument for studies needing to be finerenone vs “active comparator” falls flat when the so-called active comparator has not been shown to be better than placebo in these populations. The argument makes more sense for ASI vs nsMRA than it does for nsMRA vs sMRA.
5 542Views
21Likes
6Reposts
2Replies
0Quotes
5Bookmarks
Is that a lot?
0.42×vs this author's median13 128 views is typical
33Percentile for this authorof 6 recent posts
1.46×vs 10K–100K median3 808 views is typical
27.29%Reachviews ÷ followers
0.52%Engagement rateof viewers reacted